Capstan Therapeutics is advancing first-in-class in vivo chimeric antigen receptor (CAR) therapies that could have applicability across a wide range of therapeutic areas from a high-profile team of founding scientists, with financing from a cross-section of big pharma names and venture capital firms. The goal is to combine mRNA and CAR technologies to develop cell therapies that can be easily administered to patients.
The company announced a $102m series A financing on 14 September, building on a $63m seed funding round late last year. Capstan also announced the appointment of CEO Laura Shawver, most recently CEO of Silverback Therapeutics, Inc., a platform technology company developing tissue-targeted therapeutics for the treatment of chronic viral infections, cancer and other serious diseases, but that recently merged into ARS Pharmaceuticals, Inc.. Before that, she was CEO of Synthorx, Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
